- Stocks
- Cement & Materials
- Indo Us Biotech
Indo Us Biotech share price
NSE: INDOUSCement & MaterialsAgricultural Inputs
Indo Us Biotech at a glance
Indo Us Biotech (NSE: INDOUS) closed at ₹67.96 on 22 Oct 2026, down 0.06% on the day. With a market capitalisation of ₹136 Cr, it ranks 2481st by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Cement & Materials sector; its industry is Agricultural Inputs.
At its last close the stock traded at 10.4× trailing earnings, against a return on equity of 13.1% in FY22. Over the past year the share price has fallen 47.3%. Its 52-week range is ₹65.00 (21 Oct 2026) to ₹159.00 (27 Nov 2025); the last close is 57.3% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹26 Cr (−22.0% year on year) and net profit ₹2 Cr (−46.5%), on a standalone basis. Promoters held 68.29% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹136 CrRank 2481 on NSE
- P/E (trailing)
- 10.4×
- Price to book
- 1.61×FY22
- EPS (TTM)
- ₹6.54to Q4 FY26
- ROE
- 13.1%FY22
- ROCE
- 15.0%FY22
- Debt to equity
- 0.33FY22
- Net profit margin
- 10.1%FY22
- Book value / share
- ₹42.01FY22
- Dividend payout
- 3.0%FY22
- 52-week high
- ₹159.0027 Nov 2025
- 52-week low
- ₹65.0021 Oct 2026
- 1-year return
- −47.3%
- RSI (14-day)
- 28.4
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −0.06% | −6.9% | −13.4% | −21.5% | −47.3% |
Indo Us Biotech quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹25 Cr | ₹22 Cr | ₹24 Cr | ₹33 Cr | ₹31 Cr | ₹31 Cr | ₹23 Cr | ₹26 Cr |
| Revenue YoY | +29.2% | +40.2% | +6.6% | +111.7% | +24.5% | +39.2% | −3.2% | −22.0% |
| Net profit | ₹3 Cr | ₹4 Cr | ₹5 Cr | ₹4 Cr | ₹5 Cr | ₹3 Cr | ₹3 Cr | ₹2 Cr |
| Net profit YoY | +33.8% | +161.1% | +37.2% | +607.7% | +48.3% | −20.9% | −40.6% | −46.5% |
| Net margin | 12.8% | 19.7% | 21.4% | 11.0% | 15.3% | 11.2% | 13.2% | 7.6% |
| EPS | ₹1.58 | ₹2.16 | ₹2.52 | ₹1.86 | ₹2.35 | ₹1.72 | ₹1.49 | ₹0.98 |
Indo Us Biotech financials
| Item | FY20 | FY21 | FY22 |
|---|---|---|---|
| Revenue | ₹40 Cr | ₹40 Cr | ₹50 Cr |
| Operating profit | ₹3 Cr | ₹4 Cr | ₹5 Cr |
| Net profit | ₹3 Cr | ₹5 Cr | ₹5 Cr |
| EPS (₹) | ₹4.00 | ₹8.00 | ₹8.00 |
| Cash from operations | −₹1 Cr | ₹0 Cr | ₹3 Cr |
| Total debt | ₹1 Cr | ₹3 Cr | ₹4 Cr |
| Shareholders' equity | ₹16 Cr | ₹21 Cr | ₹39 Cr |
Indo Us Biotech shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 70.17% | 70.17% | 70.17% | 70.17% | 68.29% | 68.29% |
| Foreign institutions | 0.00% | — | — | — | 0.18% | 0.01% |
| Non-institutions | 29.83% | 29.83% | 29.83% | 29.83% | 31.53% | 31.70% |
Indo Us Biotech vs peers
The listed Cement & Materials companies nearest to Indo Us Biotech by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| KAIRAKaira Can | — | — | — | ₹143 Cr | — | — |
| PRIMAPLAPrima Plastics | — | — | — | ₹143 Cr | — | — |
| DUROPLYDuroply Industr | — | — | — | ₹140 Cr | — | — |
| INDOUSIndo Us Biotech | ₹67.96 | −0.06% | −47.3% | ₹136 Cr | 10.4 | — |
| TEXMOPIPESTexmo Pipes and Products | ₹46.70 | −2.71% | −12.6% | ₹136 Cr | 9.8 | — |
| WIPLThe Western India Plywoods | ₹160.00 | −2.39% | −1.6% | ₹136 Cr | 186 | — |
| HPILHindprakash Industries | ₹116.20 | −7.03% | −9.9% | ₹133 Cr | 48.4 | — |
Ask anything about Indo Us Biotech
Pivot answers on the live chart with evidence you can check, and tests strategies against INDOUS's own history. Try: “Why has INDOUS moved over the last three months?” · “Backtest a 50-day moving-average crossover on INDOUS over five years” · “Compare INDOUS with KAIRA on margins and valuation”
Frequently asked questions about Indo Us Biotech
What is the share price of Indo Us Biotech today?
Indo Us Biotech (NSE: INDOUS) last closed at ₹67.96 on 22 Oct 2026. Its 52-week high is ₹159.00 and its 52-week low is ₹65.00.
What is the market cap of Indo Us Biotech?
Indo Us Biotech's market capitalisation is ₹136 Cr (₹136 Cr) at the 22 Oct 2026 close, ranking 2481st among the NSE companies Pivot tracks.
What is the P/E ratio of Indo Us Biotech?
Indo Us Biotech trades at a trailing P/E of 10.4. The median P/E of the 3 closest Cement & Materials peers by market cap is 48.4.
What is the ROE and ROCE of Indo Us Biotech?
Return on equity was 13.1% in FY22 and return on capital employed was 15.0% in FY22 (consolidated figures).
Is Indo Us Biotech a debt-free company?
No. Indo Us Biotech's debt-to-equity ratio was 0.33 in FY22, with total debt of ₹4 Cr.
What were Indo Us Biotech's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Indo Us Biotech reported revenue of ₹26 Cr, −22.0% year on year, and net profit of ₹2 Cr, −46.5% year on year.
How has Indo Us Biotech stock performed over the last year?
Indo Us Biotech's share price has fallen 47.3% over the past year, −21.5% over three months and −13.4% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Indo Us Biotech?
As of 30 Jun 2026: promoters 68.29%, foreign institutions 0.01%, non-institutions 31.70%.
Who are Indo Us Biotech's competitors?
The listed Cement & Materials companies closest to Indo Us Biotech by market cap are Kaira Can, Prima Plastics, Duroply Industr, Texmo Pipes and Products, The Western India Plywoods and Hindprakash Industries.
Is Indo Us Biotech a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Indo Us Biotech's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on INDOUS against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Cement & Materials stocks · companies starting with I · all NSE stocks · this page as text